Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo-UNIFESP, São Paulo, Brazil.
Infectious Diseases Discipline, Laboratório Especial de Microbiologia Clínica-LEMC/ALERTA, EPM, UNIFESP, São Paulo, Brazil.
Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S29-S37. doi: 10.1093/cid/ciad260.
Carbapenemase production is a global public health threat. Antimicrobial resistance (AMR) data analysis is critical to public health policy. Here we analyzed carbapenemase detection trends using the AMR Brazilian Surveillance Network.
Carbapenemase detection data from Brazilian hospitals included in the public laboratory information system dataset were evaluated. The detection rate (DR) was defined as carbapenemase detected by gene tested per isolate per year. The temporal trends were estimated using the Prais-Winsten regression model. The impact of COVID-19 on carbapenemase genes in Brazil was determined for the period 2015-2022. Detection pre- (October 2017 to March 2020) and post-pandemic onset (April 2020 to September 2022) was compared using the χ2 test. Analyses were performed with Stata 17.0 (StataCorp, College Station, TX).
83 282 blaKPC and 86 038 blaNDM were tested for all microorganisms. Enterobacterales DR for blaKPC and blaNDM was 68.6% (41 301/60 205) and 14.4% (8377/58 172), respectively. P. aeruginosa DR for blaNDM was 2.5% (313/12 528). An annual percent increase for blaNDM of 41.1% was observed, and a decrease for blaKPC of -4.0% in Enterobacterales, and an annual increase for blaNDM of 71.6% and for blaKPC of 22.2% in P. aeruginosa. From 2020 to 2022, overall increases of 65.2% for Enterobacterales, 77.7% for ABC, and 61.3% for P. aeruginosa were observed in the total isolates.
This study shows the strengths of the AMR Brazilian Surveillance Network with robust data related to carbapenemases in Brazil and the impact of COVID-19 with a change in carbapenemase profiles with blaNDM rising over the years.
碳青霉烯酶的产生是全球公共卫生的威胁。抗菌药物耐药性 (AMR) 数据分析对公共卫生政策至关重要。在这里,我们使用 AMR 巴西监测网络分析了碳青霉烯酶检测趋势。
评估了包含在公共实验室信息系统数据集中的巴西医院的碳青霉烯酶检测数据。检测率 (DR) 定义为每年每个分离株通过基因测试检测到的碳青霉烯酶数量。使用普赖斯-温斯坦回归模型估计时间趋势。确定了 2015 年至 2022 年期间 COVID-19 对巴西碳青霉烯酶基因的影响。使用 χ2 检验比较了大流行前(2017 年 10 月至 2020 年 3 月)和大流行后(2020 年 4 月至 2022 年 9 月)的检测情况。使用 Stata 17.0(StataCorp,College Station,TX)进行分析。
共检测了所有微生物的 83282 株 blaKPC 和 86038 株 blaNDM。肠杆菌科细菌 blaKPC 和 blaNDM 的检测率分别为 68.6%(41301/60205)和 14.4%(8377/58172)。铜绿假单胞菌 blaNDM 的检测率为 2.5%(313/12528)。观察到 blaNDM 的年增长率为 41.1%,肠杆菌科 blaKPC 的年增长率为-4.0%,铜绿假单胞菌 blaNDM 的年增长率为 71.6%,blaKPC 的年增长率为 22.2%。2020 年至 2022 年,肠杆菌科、ABC 和铜绿假单胞菌的总分离株分别增加了 65.2%、77.7%和 61.3%。
本研究展示了 AMR 巴西监测网络的优势,提供了与巴西碳青霉烯酶相关的强大数据,并显示了 COVID-19 的影响,碳青霉烯酶谱发生了变化,blaNDM 多年来呈上升趋势。